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The analysis of data arising from retrospective studies traditionally followed methods
involving estimation of relative risks and/or odds ratios. Little attention was given to
estimation of risks, presumably due to constraint of such experimental designs, as well
as the ease of modelling of odds ratio by logistic regression. Here we present some
results for the estimation of risks in a general 2 by k contingency table setting, for a
dichotomous outcome variable and under some reasonable assumption of prevalence.
We also examine the properties of proposed estimators, and apply them to a large-
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The case-control study is a primary tool for the study of factors related to disease in-
cidence and is widely used in clinical and epidemiological research. Such studies often
utilize a retrospective design, in which the investigator looks backwards and examines
exposures to suspected risk or protection factors in relation to an outcome that is estab-
lished at the start of the study. Compared to a prospective or cohort study that almost
always involves following up the subjects over an extended period of time, a case-control
study has the advantage of being able to yield results from presently collectible data,
using relatively small amount of resources. It also reduces the sample size required to
capture a reasonable number of cases, especially when the disease under investigation is
rare in the general population.
In case-control studies, direct estimation of (absolute) risk is usually not possible as
the number of cases and controls are determined without knowledge of how many cases
and controls actually exist in the population of interest. On the other hand, one can
estimate the odds ratio, a particularly useful measure of association due to its invariance
property under retrospective and prospective sampling schemes. An odds ratio of 1 is
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indicative of statistical independence between exposure and disease outcome. Moreover,
it is well known that when disease incidence is low, the odds ratio closely approximates
the relative risk.
1.2 Background
Consider the use of a baseline categorical variable X with k levels to predict a binary
outcome Y . As an example X can be exposure to dierent levels of a risk factor and Y
the incidence of disease. A case-control study with retrospective sampling scheme will
then be to collect data from a sample of n1: controls and n2: cases of the two underlying
populations. Classication of these n1: + n2: = n:: subjects according to factor X gives
rise to a 2 k contingency table, as shown below, with ni:, n:i and n:: denoting the row,
column and overall totals, respectively (Table 1.1).
Control (Y = 0) n11 n12    n1k n1:
Case (Y = 1) n21 n22    n1k n2:
n:1 n:2    n:k n::
Table 1.1: A random sample classied as a 2 k contingency table
If the sample size n:: is small compared to the population, and if one further assumes
that the sample is a simple random sample, the k cell counts for row 1 and row 2 of
Table 1.1 may be modelled as a realization of two independent multinomial random
variables with total counts n1: and n2:, and unknown cell probabilities ij, i = 1; 2 and
j = 1; : : : ; k. Each multinomial probability ij is in fact the proportion of subjects in
subclass j within the diseased (i = 2) or non-diseased (i = 1) populations. In other
words, if we could cross classify the total population from which the cases and controls of
Table 1.1 were selected (Table 1.2), then ij = Nij=Ni:. In addition, the cell probabilities
of each row must sum up to 1, i.e.,
P
j ij = 1.
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Control (Y = 0) N11 N12    N1k N1:
Case (Y = 1) N21 N22    N1k N2:
N:1 N:2    N:k N::
Table 1.2: Association of factor X and disease in a population cross section
1.3 Odds ratio






Now suppose there are only two subclasses in a population, with factor X = 1; 2 respec-
tively. Invariance of the odds ratio implies that





r2=(1  r2) ; (1.1)
where ri denotes the proportion of cases among subclass i of the population, a quantity
that we will later dene as the risk for that subclass. The left hand side of the equation
is the ratio of odds of being in subclass 1 for cases over that for controls, while the right
hand side refers to the ratio of odds of being a case for subjects in subclass 1 over that
in subclass 2. It is on this basis that we are able to estimate from retrospective studies
















As discussed in the previous Section, it is usually natural to dene risk of developing
a disease for an individual belonging to any subclass to be the number of cases in that
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subclass over the total number of subjects in it. The relative risk for one subclass over the
another is then estimated by the ratio of the estimated absolute risks. More specically,
if we denote by P the proportion of population falling into the diseased group (that is,
the prevalence), by 2j the proportion of diseased group falling into a subclass j, and
by 1j the proportion of the non-diseased group falling into that subclass, then the risk
of disease for members of that subclass is
2jP
2jP + 1j(1  P ) ; (1.2)
and for non-members of the subclass
(1  2j)P
(1  2j)P + (1  1j)(1  P ) :
The relative risk is therefore
2j
1  2j
(1  2j)P + (1  1j)(1  P )
2jP + 1j(1  P ) : (1.3)






This is exactly the ratio of odds of being in the subclass for a control over that for a
case. Hence odds ratio can be used as an approximation to relative risk when the disease
is rare. Alternatively, this can be shown from (1.1) since






so these two quantities are similar when 1 r2
1 r1  1.
Finally, in a retrospective study as described in Table 1.1, one can estimate the odds







1.5 Motivation & organization of thesis
The relative ease of modelling, particularly through logistic regression [1], and the ap-
proximation to relative risk, has led to the widespread report of odds ratio in medical
literature. However, many researchers have reasoned that the use of odds ratio in case
control studies is technically correct, but often misleading [2]. Indeed using (1.1), one
may plot the risk parameters (r1; r2) that give rise to an odds ratio of 2, 5, 10 and 20 on
the same line (Figure 1.1). This shows that the same odds ratio can arise from dierent
risk parameters.
In this thesis we argue that estimating risks has the advantage of better interpretabil-
ity. In addition, we would also like to test the hypothesis that risks are not dierent
among the sub-populations. In doing so we need to make some assumptions, provide
the likely size of error, and discuss the bias in these estimates.



















Figure 1.1: Relationship between odds ratio and risks
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In Chapter 2 we present some theory to estimate disease risk in a general 2  k
contingency table setting. In Chapter 3 we apply the method to the Wellcome Trust
Case Control Consortium data and evaluate the performance of the method. In Chapter










i.e. the ratio of the number of cases in the subclass over the total number of subjects in
it (Table 1.2). If P , the disease prevalence is assumed to be known, and let N:: be the
population size, then the total number of cases in subclass j of the population can be
estimated by PN::n2j=n2:, and the total number of controls by (1 P )N::n1j=n1:. Hence
an estimator of risk for subclass j is
r^j =
Pn2j=n2:
Pn2j=n2: + (1  P )n1j=n1: (2.1)
except when n2j = n1j = 0. This is also an obvious estimate from (1.2) since n1j=n1: and
n2j=n2: are unbiased estimators of 1j and 2j. Indeed (2.1) is merely Bayes' theorem
which relates the prospective, disease probability (or risk) to the retrospective, exposure
probability:
rj = P(Y = 1jX = j) = PP(X = jjY = 1)
PP(X = jjY = 1) + (1  P )P(X = jjY = 0)
where we used Y = 1; 0 to denote a subject being a case and control, respectively.
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2.2 Expectation
Since n1: and n2: are xed, and P is a constant for a given population at the time of
study, each nij has a marginal binomial distribution with parameters ni: and ij. We



















while the true value of parameter rj is given by (1.2). The bias can be obtained by
taking the dierence between (2.2) and (1.2) and plotting graphically for all 1j and 2j.
When both n1j and n2j are 0, the risk rj is not estimable. Hence in computing (2.2)
we have to \ignore" the case of k = l = 0. In addition when n1j or n2j is 0, the estimator
(2.1) would give 1 or 0, and inclusion of these outcomes might inuence substantially
the bias of the estimator. Since the estimator will not be used in these situations, it
might be better to consider instead the conditional expectation E(r^jjn1j; n2j > 0). It is
linked to E(r^j) via the relationship
E(r^jjn1j; n2j > 0) = E(r^j)  S1
1  S1   S2 ;
where
















In practice however, we nd that the dierence between E(r^jjn1j; n2j > 0) and E(r^j) is




Wiggins and Slater [3] previously discussed a similar problem where it was assumed that
all cases of the disease in the population were captured. A random sample was then
selected from the control population. They proposed a numerical approximation to the
expectation and variance of the risk estimates. More specically, if the total number of
cases in the population is known, i.e. n2: = N2: then N:: = n2:=P and each n2j is no
longer random. The estimator (2.1) can be written as
r^j =
n2j
n2j + (1  P )n1jn2:=Pn1: =
Pn1:n2j
Pn1:n2j + (1  P )n2:n1j : (2.3)
Notice that in the above expression n1j is the only random component. The expectation











The expectation can be approximated using a Taylor expansion argument. Let  =
P=(1  P ), we nd













































































Using (1  x) 1 =P1k=0 xk, one can expand E(r^j) in a power series and ignore powers
of 3 and higher to nd













Similarly, one can expand E(r^2j ) in a power series and ignore the powers of 
3 and
higher to get













In the above derivation, the model is built upon the assumption that all cases in the
population are captured, and only the number of controls in the sample is treated as
random. While this assumption might hold for certain severe, rapid-onset disease that
are under extensive surveillance, it certainly does not apply to most common diseases
that are of public health interest. Consequently it is necessary to allow uncertainty in
both cases and controls.
2.4 Testing equality of risks
It is often of interest to study whether a risk factor X is associated with the disease
outcome. The classic test of homogeneity between two multinomial probabilities in







where Oij = nij are the observed counts and Eij = ni:n:j=n:: are the expected counts in
the (i; j) cell, under the null hypothesis that the multinomial probabilities of row 1 and
row 2 are the same, i.e.
1j = 2j for i = 1; : : : ; k;
which is equivalent to H0 : r1 = r2 = r3. The alternative hypothesis is H1 : 1j 6=
2j for at least one of 1; : : : ; j. For large sample sizes, the approximate null distribution
of this statistic is 2 with (2  1) (k   1) = k   1 degrees of freedom [4].
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An alternative is the likelihood ratio test, which is asymptotically equivalent to the
2 test. The cells counts of two rows in Table 1.1 follow approximately the multinomial
distributions with joint frequency function














The two multinomial distributions are independent, and the log likelihood function is
therefore






n2j log(2j) + C;
subject to the constraint that
P
j ij = 1 for i = 1; 2. Alternatively, one can express
l(11; : : : ; 2k) in terms of the `free' parameters, i.e.
l(11; : : : ; 1(k 1); 21; : : : ; 2(k 1)) =
k 1X
j=1











The null hypothesis H0 : r1 =    = rk is equivalent to the multinomial probabilities of
row 1 and row 2 of Table 1.1 being equal. Under H0, (2.7) is maximized at







or equivalently, r^1 =    = r^k = P . Under the alternative hypothesis, there is no
restriction on ij's so (2.7) is maximized at the MLEs ^ij = nij=ni:. The test statistic
is therefore
 =  2(l0   l1);
where l0 and l1 denote the maximized log likelihood under the parameter space specied
by the null and alternative hypotheses, respectively. The degree of freedom is calculated
as follows: under H0, there are 2k   2 free parameters due to the two constraints of
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summing up to 1. Under H1, the two rows have the same multinomial probabilities so
there are k   1 free parameters. The test statistic therefore follows an asymptotic 2
distribution with k   1 degrees of freedom.
It shall be made clear that although incorporation of the prevalence P is required
for estimation of risks, it is not needed in the tests. Reparametrization from  to r does
not change the maximum likelihood or the likelihood ratio test statistic.
2.5 Cochran-Armitage test
We also consider a third test, the Cochran-Armitage test [5, 6] which utilizes ordered
categories in a contingency table and tests for a linear trend based on a score xi assigned
to each column of Table 1.1. It uses a linear probability model
pi = + xi;
where pi is the expected proportion of cases in the ith subclass in the sample. Note
that pi diers from ri by a factor that is constant across all the subclasses, as a result
of retrospective sampling. Hence the null hypothesis of independence H0 :  = 0 is
equivalent to H0 : r1 =    = rj.
The test may be rationalized with an analysis of variance approach. More speci-













i=1 n:i(p^i   p^)2
p^(1  p^) :
with the weights being n:i=p^(1  p^). Here p^i is the observed proportion of cases in the ith
subclass and p^ is the overall proportion of cases in the sample. The regression parameter
17
 can then be obtained by the standard formula for weighted regression
^ =
P
i n:i(p^i   p^)(xi   x)P
i n:i(xi   x)2
;






It is then possible to subdivide this weighted sum of squares by the rules of analysis of









p^(1  p^)Pi n:i(xi   x)2






where ^^pi = ^+ ^xi is the tted value for pi.
The Cochran-Armitage test statistic is simply SSR and it tests H0 :  = 0. When
the linear probability model holds, SSR is asymptotically 





We now apply the methods in Chapter 2 to data from the main experiment of the
Wellcome Trust Case Control Consortium: a genome-wide association study involving
2,000 DNA samples from each of seven diseases (type 1 diabetes, type 2 diabetes, coro-
nary heart disease, hypertension, bipolar disorder, rheumatoid arthritis and Crohn's
disease) [7]. As is typical for GWA studies, a dense set of single-nucleotide polymor-
phisms (SNPs) across the genome is genotyped, and statistical analysis is performed
to survey the most common genetic variation that is associated with risk factors for
disease. An SNP is a DNA sequence variation occurring when a single nucleotide (A, T,
C, or G) in the genome or other shared sequence diers between members of a species.
The associated SNP markers are then considered as pointers to the region of the human
genome where the disease-causing gene is likely to reside.
3.1 Data description
We choose to analyze the data from type-2 diabetes, partly because of the availability
of some reasonably reliable prevalence data [8]. In this study, a total number of 2938
controls and 1924 cases are genotyped, after excluding samples with contamination, false
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identity, non-Caucasian ancestry and relatedness. The case samples are ascertained from
sites widely distributed across Great Britain, and the controls come from two sources:
about 1500 are representative samples from the 1958 British Birth Cohort and another
1500 are blood donors recruited by the three national UK Blood Services.
Summary genotype statistics were retrieved from the European Genotype Archive
(http://www.ebi.ac.uk/ega/page.php) and they contained data on over ve hundred
thousand SNPs distributed over 23 chromosome pairs of the approximately 5000 par-
ticipants in the study. All SNPs are biallelic, i.e. there are only 2 alleles that usually
dier by a single nucleotide, giving rise to 3 possible genotypes. The controls and cases
are classied according to their genotypes at the SNP site, making this an application
of the theory with k = 3.
3.2 Bias
We rst evaluate the bias of risk estimates corresponding to dierent parameter values
1j and 2j. Since rj is undened when 1j = 2j = 0, we assume hereafter that at least
one of 1j and 2j is not 0. Comparing the expressions (2.2) and (1.2) it is easy to see
that the bias of r^j is 0 when either 1j or 2j is 0, and when both 1j and 2j are 1.
Let n1: = 3000, n2: = 2000, and prevalence P = 0:039 for type 2 diabetes, the
(unconditional) biases (2.2) for selected values of 1j and 2j are plotted (Figure 3.2).
In general the bias decreases with 1j, and increases with 2j. Nonetheless, in most
cases of the WTCCC study, the biases are small and negligible.
3.3 Variance
Since the exact form of standard errors (SE) of the risk estimates is dicult to compute,
they are estimated by simulation: rst x some selected multinomial probabilities 1j
20

























































































Figure 3.1: Bias of risk estimates
and 2j, j = 1; : : : ; 3, then generate using these parameters 5000 2  3 tables. Monte
Carlo simulation is then performed with n = 106 repeats with estimated multinomial
parameters from each of these 5000 tables. The variance-covariance matrix can then be
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obtained from the 106 risk estimates. Table 3.1 gives the mean and standard deviation of
the a diagonal (Var(r^1)) as well as an o-diagonal element (Cov(r^1; r^3)) of 5000 variance-
covariance matrices. It is clear while the Monte Carlo approach works well in most cases,
the estimated SE of risk estimates can be very poor at extreme parameter values.
Parameter Mean SD MC
(0:3; 0:3; 0:4)
Var(r^1) 2:75 10 6 2:18 10 7 2:74 10 6
Cov(r^1; r^3)  1:17 10 6 5:48 10 8  1:17 10 6
(0:1; 0:1; 0:8)
Var(r^1) 1:08 10 5 1:66 10 6 1:06 10 5
Cov(r^1; r^3)  1:18 10 6 9:09 10 8  1:17 10 6
(0:01; 0:01; 0:98)
Var(r^1) 1:55 10 4 9:66 10 5 1:32 10 4
Cov(r^1; r^3)  1:25 10 6 3:47 10 7  1:22 10 6
(0:005; 0:005; 0:99)
Var(r^1) 5:12 10 4 1:03 10 3 3:11 10 4
Cov(r^1; r^3)  1:35 10 6 5:59 10 7  1:28 10 6
Table 3.1: Mean and SD of 5000 estimated variance Var(r^1) as well as covariance
Cov(r^1; r^3) generated using estimated parameter values. MC is the simulated variance
and covariance using actual parameters.
3.4 Risk estimation
Data from a total number of 420,172 SNPs distributed over 22 chromosome pairs are
analyzed. For each SNP, we denote by rmax and rmin the maximum and minimum risks
among the three genotypes, respectively. Table 3.2 provides the ve number summary
as well as the mean of the distribution of rmax and rmin in all the SNPs.
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Min 1st Quartile Median Mean 3rd Quartile Max
rmax 0.0390 0.0399 0.0408 0.0436 0.0428 0.526
rmin 0.00237 0.0356 0.0373 0.360 0.0382 0.0390
Table 3.2: Five number summary of distribution of risks
3.5 Tests of association
We applied the three tests described in Section 2.3, i.e. the likelihood ratio, 2 and
Cochran-Armitage tests with score f0; 1; 2g to the type 2 diabetes data. The rationale
for choosing this score is based on the assumption that any eect of the disease-causing
allele, if present, will be proportional to the number of such allele an individual carries. A
total number of 32 SNPs with at least one of the P -values below 510 7 were detected.
Based on the WTCCC study, this is the threshold below which a strong association
between SNP and underlying disease is declared. Table 3.3 shows the P -values as well
as the estimated risks for these SNPs.
Of these 32 SNPs, 16 are found with poor clustering and removed from the analysis.
The remaining 16 SNPs form 4 clusters. Three of them, located on chromosomes 6, 10
and 16 coincide with the WTCCC study results [7], but a fourth SNP on chromosome
3 (rs2314349) has not been reported. The reason for the discrepancy is not clear. It is
possible that the SNP did not pass through the quality control lters in the WTCCC
study.
Of the 3 SNP clusters that exhibit strong association signal, one located on chromo-
some 10 and represented by rs4506565 has the lowest P -values. This SNP is within a
previously reported transcription factor 7-like 2 gene (TCF7L2) [9]. The association is
possibly explained by its action through regulation of pro-glucagon gene expression in
enteroendocrine cells via the Wnt signaling pathway [10].
The second signal is from the FTO or fat-mass and obesity associated gene on
chromosome 16 (rs9939609). It was previously hypothesized that the eect of this variant
23
on type 2 diabetes risk is mediated entirely by its eect on adiposity [11].
The third association signal on chromosome 6 features a cluster of highly associated
SNPs (including rs9465871) that map to intron 5 of the CDK5 regulatory subunit asso-
ciated protein 1-like 1 (CDKAL1 ) gene. The exact function of CDKAL1 is not clearly
understood, but it shares homology at the protein domain level with CDK5 regulatory
subunit associated protein 1 (CDK5RAP1). CDK5RAP1 is known to inhibit the acti-
vation of CDK5, a cyclin-dependent kinase which is involved in cell proliferation and
maintenance of normal beta-cell function [12].
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Chr SNP Trend P -value 2 P -value r^AA r^AB r^BB Cluster
3 rs2314349 0.003501860 4:669716 10 7 0.036 0.049 0.022 1
6 rs9465871 1:019692 10 6 3:341986 10 7 0.075 0.042 0.036 1
10 rs7901275 3:085252 10 8 2:166514 10 7 0.032 0.039 0.049 1
10 rs4074720 5:216261 10 11 2:794187 10 10 0.052 0.038 0.031 1
10 rs7901695 6:742384 10 13 5:616127 10 12 0.058 0.042 0.032 1
10 rs4506565 5:706546 10 13 5:048329 10 12 0.058 0.042 0.031 1
10 rs4132670 1:883049 10 12 1:644901 10 11 0.057 0.042 0.031 1
10 rs10787472 2:009426 10 11 1:226463 10 10 0.052 0.038 0.030 1
10 rs12243326 1:791796 10 10 1:017059 10 9 0.033 0.042 0.059 1
10 rs7077039 2:846168 10 12 1:331970 10 11 0.053 0.038 0.030 1
10 rs11196205 7:015932 10 11 2:652307 10 10 0.052 0.038 0.031 1
10 rs10885409 8:47945 10 11 3:482646 10 10 0.031 0.038 0.052 1
10 rs11196208 5:532075 10 11 3:058625 10 10 0.031 0.038 0.052 1
16 rs7193144 1:446072 10 8 4:775441 10 8 0.031 0.042 0.048 1
16 rs8050136 2:007310 10 8 7:038900 10 8 0.048 0.042 0.031 1
16 rs9939609 5:261009 10 8 1:907746 10 7 0.031 0.042 0.048 1
1 rs13373826 0.1316872 1:282534 10 7 0.0067 0.042 0.039 0
2 rs4080478 0.9508418 3:568200 10 8 0.18 0.033 0.040 0
4 rs16837871 < 2:2 10 16 2:322810 10 35 0.042 0.018 0.047 0
4 rs13126272 1:432675 10 5 3:499818 10 22 0.070 0.030 0.039 0
5 rs4270702 0:8052082 9:790488 10 8 0.0026 0.045 0.038 0
5 rs2048646 0:04385808 3:406096 10 17 0.040 0.031 0.083 0
6 rs1324132 6:775095 10 7 1:837621 10 9 0.045 0.030 0.037 0
6 rs10499044 < 2:2 10 16 5:720925 10 23 0.044 0.019 0.030 0
7 rs1525791 1:616481 10 6 1:694865 10 7 0.035 0.051 0.035 0
9 rs488101 1:158367 10 6 1:039887 10 10 0.038 0.032 0.048 0
14 rs1957779 2:057396 10 5 1:777778 10 8 0.028 0.044 0.041 0
14 rs1362719 3:089134 10 5 6:708994 10 10 0.038 0.032 0.050 0
15 rs597414 0.01221369 2:115368 10 8 0.044 0.030 0.047 0
16 rs9889057 0.0001041203 2:369359 10 20 0.050 0.027 0.046 0
21 rs226261 4:280764 10 7 2:270588 10 36 0.040 0.027 0.075 0
22 rs11705626 < 2:2 10 16 1:399167 10 93 0.032 0.0024 0.049 0
Table 3.3: 32 SNPs with strong association. Chr: Chromosome. Cluster: a binary




Following the great triumph of the case-control study which demonstrated of the link
between tobacco smoking and lung cancer [13], this study design has gained wide recog-
nition. However, their retrospective, non-randomized nature limits the conclusions that
can be drawn from them.
In this thesis we outlined the general methodology of obtaining risk estimates. We
also discussed their statistical properties such as bias and standard error. We concluded
that when one has some reasonable cell counts, the bias of the estimates is small and
the standard error can be estimated. Compared to the conventional tests of association
and trend which only tells a signicant departure from the null hypothesis, being able
to estimate the risk allows one to decide the direction of association. We consider this
an added advantage and argue that it is better to deal with risks, because they are more
interpretable. Ease of modelling should not be a general justication for using odds,
although it can be for some cases.
The assumption of prevalence is key to estimation of risks. Deviations of the true
prevalence from the assumed value will not aect the statistical signicance of the tests,
but it will inuence the estimates and thus the (perceived) eect size, i.e. the practical
sigicance. This judgment of practical importance is beyond statistical analysis, but we
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are well-advised to be aware of its place in scientic research.
Our methods apply to general case-control studies, and also GWA studies in par-
ticular. We are aware that GWA studies, or genetic linkage and association studies
in general, involves not only investigating individual SNP in isolation, and that GWA
approach has intrinsic problems such as multiple testing that can result in an unprece-
dented potential for false-positive results [14]. Nonetheless, we think that incorporation
of risk assessment into genetic analysis might present an alternative way of dealing with
data generated from such studies.
Finally, it is worth noting that while prospective studies can estimate the relative
risk with respect to becoming sick (incidence), retrospective studies can estimate only
the relative risk with respect to being sick (prevalence). The practical importance of
this distinction may be enormous. For disease that is usually associated with increased
mortality risk such as myocardial infarction, retrospective studies that compare existing
cases with controls on one or more risk factors cannot in principle relate to all cases
occurring during the past n years because some of these incidence cases may no longer
be alive. Hence in such situations the (relative) risks derived from retrospective studies
may be quite dierent from those obtained in prospective studies.
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Proof of (2.4). From (2.3) and  = P=(1  P ) we have that
r^j =
Pn1:n2j




















































Proof of (2.5). Dropping the subscript for 1j and writing n1: = N , we can prove (2.5)






































































































































































































Substituting this into (4.1) gives in the desired results.
Proof of (2.6). The proof of Y2 is similar. First observe that the equality holds when
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where we have made use of the results from Y1. Substituting this into the above yields
the desired equality.
32
